Page 8 - உலகம் புற்றுநோய் ஆராய்ச்சி நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

rostate canc er) is a Phase I/IIa study for identification and treatment of PSMA-expressing metastatic castrate resistant prostate cancer (mCRPC), which will be conducted in the U.S. (NCT04868604) [1]. It is a theranostic multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients. The trial employs diagnostic Positron Emission Tomography imaging with 64Cu-SAR-bisPSMA for selection of patients suitable for therapy cycles with 67Cu-SAR-bis-PSMA. Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of death worldwide [2]. The American Cancer Society estimates in 2021 there will be 248,530 new cases of prostate cancer in the U.S. and around 34,130 deaths from the disease

United statesNew south walesAlan taylorClarity global clinical development groupNational institute of healthTechnology platformDrug administrationPrnewswire clarity pharmaceuticalsWorld cancer research fundClarity pharmaceuticalsUs national library of medicineCancer statistics centerAmerican cancer societyClinical cancer researchInvestigational new drugProstate specific membrane antigen